CONMED (NYSE:CNMD) Stock Rating Upgraded by Wall Street Zen

Posted by Francis Steltz on Jul 22nd, 2026

CONMED (NYSE:CNMD – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Monday.

Several other research firms also recently issued reports on CNMD. BMO Capital Markets started coverage on CONMED in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 target price on the stock. Zacks Research cut CONMED from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Wells Fargo & Company set a $39.00 price target on CONMED in a research report on Monday, July 13th. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Finally, Bank of America reaffirmed an “underperform” rating and set a $40.00 target price on shares of CONMED in a report on Monday, June 29th. Five analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, CONMED currently has a consensus rating of “Reduce” and a consensus target price of $38.80.

Get Our Latest Stock Report on CONMED

CONMED Trading Down 3.6%

CONMED stock opened at $41.90 on Monday. The stock has a 50-day moving average of $36.09 and a two-hundred day moving average of $38.37. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. CONMED has a one year low of $31.44 and a one year high of $56.63. The stock has a market cap of $1.26 billion, a PE ratio of 23.67, a price-to-earnings-growth ratio of 3.21 and a beta of 0.93.

CONMED (NYSE:CNMD – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $317.05 million for the quarter, compared to analyst estimates of $310.64 million. CONMED had a net margin of 4.00% and a return on equity of 13.84%. CONMED’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.95 EPS. On average, research analysts anticipate that CONMED will post 4.38 EPS for the current fiscal year.

Institutional Investors Weigh In On CONMED

A number of institutional investors have recently modified their holdings of CNMD. Kestra Advisory Services LLC acquired a new stake in CONMED in the 4th quarter valued at $26,000. Kelleher Financial Advisors acquired a new position in CONMED during the third quarter worth $28,000. Aster Capital Management DIFC Ltd raised its position in CONMED by 409.2% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock worth $29,000 after acquiring an additional 581 shares during the period. Versant Capital Management Inc lifted its holdings in CONMED by 210.8% during the second quarter. Versant Capital Management Inc now owns 1,125 shares of the company’s stock valued at $37,000 after purchasing an additional 763 shares in the last quarter. Finally, Quarry LP lifted its holdings in CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after purchasing an additional 617 shares in the last quarter.

About CONMED

(Get Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.